DNA testing company 23andMe has filed for bankruptcy protection and is seeking a court-supervised sale amid financial challenges. The resignation of CEO Anne Wojcicki has prompted uncertainty regarding the handling of personal data held by the company, which serves around 15 million customers. Concerns have risen over potential misuse of genetic data by future buyers. The company aims to maximize its value through this legal process while addressing significant operational and financial issues, alongside resolution of liabilities. Experts emphasize the importance of protecting customer data rights during the bankruptcy process.
DNA testing company 23andMe has filed for bankruptcy protection, raising questions about the future of the company and the personal data it holds.
After a thorough evaluation of strategic alternatives, we have determined that a court-supervised sale process is the best path forward to maximize the value of the business.
Ideally, the court appointed trustee has a view and understanding of the sensitivity of the data, the corporate and legal constraints, and the regulatory implications.
The data itself is one of the core assets, and technically that would be of interest to a buyer.
Collection
[
|
...
]